Establishment Labs Highlights Breast Tissue Preservation Data and New Minimally Invasive Products
Establishment Labs Presents New Breast Tissue Preservation Data and Expands Minimally Invasive Platform at WSEI Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company focused on advancing women’s…
Therapy Becomes the Default Response to Everyday Stress as Employers Expand Coverage
Therapy Gains Ground as a Go-To Solution for Everyday Stress and Social Connection Modern Health, a global workplace mental health platform, has released new international research examining how employees use…
Alkermes Reports Positive Phase 1b Results for ALKS 7290 in ADHD
Alkermes Reports Positive Phase 1 Results for Investigational Orexin 2 Receptor Agonist ALKS 7290 in Adult ADHD Alkermes plc (Nasdaq: ALKS) has announced positive topline results from a Phase 1…
Iambic Launches Enchant v3 to Advance End-to-End Drug Discovery and Development
Iambic Launches Enchant v3 to Advance AI-Driven End-to-End Drug Discovery Iambic, a clinical-stage life science and technology company developing novel medicines through an artificial intelligence-driven platform, has unveiled Enchant v3,…
Merck’s KEYTRUDA QLEX Approved in Japan Across All KEYTRUDA Indications
Merck’s KEYTRUDA QLEX Approved in Japan for Subcutaneous Use Across KEYTRUDA Indications Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Japan’s Ministry of Health,…
Medincell Partner Teva Presents New Data on Investigational Olanzapine LAI and UZEDY at Psych Congress 2026
Medincell Partner Teva Presents New Data on Investigational Olanzapine LAI and UZEDY at Psych Congress 2026 Medincell’s partner Teva Pharmaceuticals presented new clinical and real-world data on two long-acting injectable…
Bristol Myers Squibb Reports Durable Efficacy and Consistent Safety With Sotyktu in Psoriatic Arthritis Over Two Years
Bristol Myers Squibb Reports Two-Year Data Showing Durable Sotyktu Efficacy in Psoriatic Arthritis Bristol Myers Squibb (NYSE: BMY) announced positive two-year results from the Phase 3 POETYK PsA-2 study and…
Novartis’ Cosentyx Receives Positive CHMP Opinion for Polymyalgia Rheumatica
Novartis’ Cosentyx Receives Positive CHMP Opinion for Polymyalgia Rheumatica in Europe Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…
Roche’s Ocrevus Recommended for EU Approval in Children and Adolescents With Relapsing Multiple Sclerosis
Roche’s Ocrevus Gains Positive CHMP Opinion for Pediatric Multiple Sclerosis in Europe Roche (SIX: RO, ROP; OTCQX: RHHBY) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for…
Roche Opens Boston Innovation Center to Advance Cardiovascular, Renal and Metabolic Disease Research
Roche Opens Innovation Center Boston to Expand Cardiovascular, Renal and Metabolism Research Roche (SIX: RO, ROP; OTCQX: RHHBY) has officially opened the Roche Genentech Innovation Center Boston, marking a significant…
Roche’s Lunsumio-Based Regimen Improves Progression-Free Survival in Phase III CELESTIMO Study
Roche’s Lunsumio Combination Meets Primary Endpoint in Phase III CELESTIMO Trial for Relapsed or Refractory Follicular Lymphoma Roche has announced positive topline results from the Phase III CELESTIMO study evaluating…
Merck Launches “Your Hive of Whole Health” to Support Whole-Person HIV Care
Merck Launches “Your Hive of Whole Health” Program to Support Whole-Person Well-Being for People Living With HIV Merck (NYSE: MRK), known as MSD outside the United States and Canada, has…